Cantitate/Preț
Produs

Tumor Targeting in Cancer Therapy: Cancer Drug Discovery and Development

Editat de Michel Pagé
en Limba Engleză Hardback – apr 2002

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 142576 lei  43-57 zile
  Humana Press Inc. – 19 noi 2010 142576 lei  43-57 zile
Hardback (1) 143914 lei  43-57 zile
  Humana Press Inc. – apr 2002 143914 lei  43-57 zile

Din seria Cancer Drug Discovery and Development

Preț: 143914 lei

Preț vechi: 151489 lei
-5% Nou

Puncte Express: 2159

Preț estimativ în valută:
27541 28579$ 23020£

Carte tipărită la comandă

Livrare economică 17-31 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780896039193
ISBN-10: 0896039196
Pagini: 463
Ilustrații: X, 463 p. 39 illus.
Dimensiuni: 178 x 254 x 31 mm
Greutate: 1.15 kg
Ediția:2002
Editura: Humana Press Inc.
Colecția Humana
Seria Cancer Drug Discovery and Development

Locul publicării:Totowa, NJ, United States

Public țintă

Professional/practitioner

Cuprins

I. A Review.- 1 The Current Status of Tumor Targeting: A Review.- 2 Clinical Applications of Targeted Therapeutics.- II. Targeting Tumors with Drug Antibody Conjugates.- 3 Targeting the CD22 Receptor with RNA Damaging Agents.- 4 The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors.- 5 Overcoming Multiple Drug Resistance with Anti-Pgn Carrier.- 6 Targeting with Transferrin.- 7 Synthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In Vitro.- 8 The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer.- III. Targeting Tumors with Antibodies.- 9 Targeting Vascular Endothelium with Antibodies.- 10 Targeting B-Cell Non-Hodgkin’s Lymphoma with Monoclonal Antibodies.- 11 From Bench to Bedside: Development of Rituximab (Rituxan®), A Monoclonal Antibody for the Therapy of Non-Hodgkin’s Lymphoma.- 12 Mylotarg: The First Antibody-Targeted Chemotherapy Agent..- IV. Targeting Tumors with Radioimmunoconjugates.- 13 188Rhenium-Labeled Trisuccin-?CH2HuCC49 as a Radioimmunotherapy Model in Nude Mice.- V. Targeting Tumors with Immunotoxins.- 14 General Approach for Targeting Toxins.- 15 Antibody-Toxin Conjugates: Chemistry of Coupling and Purification.- 16 Shiga-Like Toxins as Targeted Anticancer Agents.- VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT).- 17 Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies.- VII. Photodynamic Therapy.- 18 Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates.- 19 Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model.- VIII. Targeting Tumors with Magnetic Drugs.- 20 Targeting Tumors with Magnetic Drugs.- IX. Principles and Techniques in Targeting.- 21 Internalization ofAntibodies.- 22 Bioconjugation and Biodistribution.- 23 Principles of Antitumor Targeting of Cytotoxic Drugs.- 24 Targeting by Antibody or Ligand: Which Is Better?.

Recenzii

"This book stands out among many books with similar titles in that it deals with topics in a sequence that best describes the fundamentals and applications of drug targeting....Each chapter of the book was well balanced to have both basic and clinical aspects. This book is highly recommended for all graduate students, researchers, and clinicians who are involved in the antibody-based drug targeting." -- Pharmaceutical Research

"Tumor Targeting in Cancer Therapy represents an outstanding work, describing both experimental and clinical application of antibodies for targeting tumors." -Neoplasma

Textul de pe ultima copertă

After many years of vigorous effort, the use of antibodies to target tumors has become highly successful both clinically and commercially. In Tumor Targeting in Cancer Therapy, Dr. Michel Pagé and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.
Comprehensive and practical, Tumor Targeting in Cancer Therapy summarizes the essentials of tumor targeting as it is practiced today and provides all those engaged in experimental and clinical cancer research the critically established information needed to evaluate new technologies, investigate novel therapeutic agents, and apply them in relevant clinical practice.

Caracteristici

Includes supplementary material: sn.pub/extras